

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

Li 1



| Section 1.  | Identifying Inform   | nation  |  |                             |
|---|--|---|--|-----------------------------|
| 1. Given Name (Fi   | rst Name)  | 2. Surname (Last Name)<br>Li                                  | 3. D<br>14- <i>J</i>   | ate<br>April-2020           |
| 4. Are you the corresponding author?                      |  | Yes ✓ No  | Corresponding Author's Name<br>Baijun Fang   |                             |
| 5. Manuscript Title<br>Preliminary stud<br>myeloma (MM) c | y on the relationship ar                                       | mong stem cell markers, di                                    | ug resistance and PI3K signaling   | g pathway in multiple       |
| 6. Manuscript Ider<br>TCR-19-2116                         | ntifying Number (if you kr                                     | now it)   |  |                             |
|   |  |   |  |                             |
| Section 2.  | The Work Under C   | onsideration for Public                                       | ation  |                             |
| any aspect of the s<br>statistical analysis,              | stitution <b>at any time</b> rece<br>submitted work (including | ive payment or services from<br>but not limited to grants, da | a third party (government, commen<br>a monitoring board, study design,   |                             |
| Section 3.  | Relevant financial   | activities outside the s                                      | ubmitted work.   |                             |
| of compensation clicking the "Add                         | n) with entities as descri                                     | ibed in the instructions. Us<br>port relationships that wer   | ether you have financial relation<br>e one line for each entity; add a<br>e <b>present during the 36 montl</b> | s many lines as you need by |
| Section 4.  | Intellectual Proper  | rty Patents & Copyrig   | hts  |                             |
| Do you have any   |  |   | padly relevant to the work?  | Yes 🗸 No                    |

Li 2



| Section 5. Polationships not sovered above   |
|--|
| Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Li has nothing to disclose.  |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Li 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Liu 1



| Section 1.  | Identifying Inform                                     | nation   |   |  |
|---|--|--|---|--|
| 1. Given Name (Fi<br>Bingshan                             | rst Name)  | 2. Surname (Last Name)<br>Liu                              | -   | . Date<br>4-April-2020   |
| 4. Are you the cor  | responding author?                                     | Yes No Corresponding Author's Name Baijun Fang             |   | 2  |
| 5. Manuscript Title<br>Preliminary stud<br>myeloma (MM) o | y on the relationship ar                               | mong stem cell markers, d                                  | rug resistance and PI3K signal                                      | ling pathway in multiple   |
| 6. Manuscript Ide<br>TCR-19-2116                          | ntifying Number (if you kr                             | now it)  |   |  |
|   |  |  |   |  |
| Section 2.  | The Work Under Co                                      | onsideration for Public                                    | cation  |  |
| any aspect of the s<br>statistical analysis,              | ubmitted work (including                               | but not limited to grants, da                              | a third party (government, comr<br>ta monitoring board, study desig | mercial, private foundation, etc.) for<br>gn, manuscript preparation,                          |
|   |  |  |   |  |
| Section 3.  | Relevant financial                                     | activities outside the s                                   | ubmitted work.  |  |
| of compensation clicking the "Add                         | n) with entities as descri<br>I +" box. You should rep | bed in the instructions. Us<br>port relationships that wer |   | ionships (regardless of amount<br>d as many lines as you need by<br>nths prior to publication. |
| Are there any rel   | evant conflicts of intere                              | est? Yes ✓ No  |   |  |
| Soction A   |  |  |   |  |
| Section 4.  | Intellectual Proper                                    | ty Patents & Copyric                                       | ıhts  |  |
| Do you have any   | patents, whether plan                                  | ned, pending or issued, br                                 | oadly relevant to the work?   | ☐ Yes ✓ No   |

Liu 2



| Section 5.              |   |
|-------------------------|---|
| Section 5.              | Relationships not covered above   |
|                         | elationships or activities that readers could perceive to have influenced, or that give the appearance of named in the submitted work?  |
| Yes, the follow         | ving relationships/conditions/circumstances are present (explain below):  |
| ✓ No other relat        | ionships/conditions/circumstances that present a potential conflict of interest   |
|                         | nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>nals may ask authors to disclose further information about reported relationships. |
| Section 6.              | Disclosure Statement  |
| Based on the aborbelow. | ve disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |
| Dr. Liu has nothir      | ng to disclose.   |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Liu 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Wang 1



| Section 1. Identifying Inform   | nation  |  |
|---|---|--|
| identifying inform  | ilation   |  |
| Given Name (First Name)  Danyang  | 2. Surname (Last Name)<br>Wang                              | 3. Date<br>14-April-2020   |
| 4. Are you the corresponding author?  | Yes 🗸 No  | Corresponding Author's Name<br>Baijun Fang   |
| 5. Manuscript Title<br>Preliminary study on the relationship a<br>myeloma (MM) cell | mong stem cell markers, d                                   | rug resistance and PI3K signaling pathway in multiple  |
| 6. Manuscript Identifying Number (if you ki   | now it)   |  |
|   |   |  |
| Section 2. The Work Under C   | onsideration for Public                                     | cation   |
|   | g but not limited to grants, da                             | a third party (government, commercial, private foundation, etc.) for<br>ta monitoring board, study design, manuscript preparation,   |
| Section 3. Relevant financial   | activities outside the s                                    | ubmitted work.   |
| of compensation) with entities as descr   | ibed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication. |
| Section 4. Intellectual Prope   | rty Patents & Copyrig                                       | ghts   |
| Do you have any patents, whether plan   | ned, pending or issued, br                                  | oadly relevant to the work? Yes V No   |

Wang 2



| Section 5.                |   |
|---------------------------|---|
| Section 5.                | Relationships not covered above   |
|                           | ationships or activities that readers could perceive to have influenced, or that give the appearance of cing, what you wrote in the submitted work?   |
| Yes, the followi          | ng relationships/conditions/circumstances are present (explain below):  |
| ✓ No other relation       | onships/conditions/circumstances that present a potential conflict of interest  |
|                           | uscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>als may ask authors to disclose further information about reported relationships. |
| Section 6.                | Disclosure Statement  |
| Based on the above below. | e disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |
| Dr. Wang has noth         | ning to disclose.   |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Wang 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Song 1



| Section 1.  | Identifying Inform                                  | nation   |  |                |
|---|---|--|--|----------------|
| 1. Given Name (Fi<br>Yongping                             | rst Name)   | 2. Surname (Last Name)<br>Song                             | 3. Date<br>14-April-2020   |                |
| 4. Are you the cor  | ou the corresponding author? Yes Volume Saijun Fang |  |  |                |
| 5. Manuscript Title<br>Preliminary stud<br>myeloma (MM) o | y on the relationship ar                            | mong stem cell markers, d                                  | ug resistance and PI3K signaling pathway in  | multiple       |
| 6. Manuscript Idei<br>TCR-19-2116                         | ntifying Number (if you kr                          | now it)  |  |                |
|   |   |  |  |                |
| Section 2.  | The Work Under Co                                   | onsideration for Public                                    | ation  |                |
| any aspect of the s<br>statistical analysis,              | ubmitted work (including                            | but not limited to grants, da                              | a third party (government, commercial, private for<br>a monitoring board, study design, manuscript pre   |                |
| Section 3.  | Relevant financial                                  | activities outside the s                                   | ubmitted work.   |                |
| of compensation clicking the "Add                         | n) with entities as descri                          | bed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regard<br>e one line for each entity; add as many lines a<br>e <b>present during the 36 months prior to pu</b> | as you need by |
| Section 4.  | Intallactual Proper                                 | ty Patents & Copyrig                                       | htc  |                |
|   |   |  |  |                |
| Do you have any   | patents, whether plan                               | nea, pending or issued, br                                 | padly relevant to the work? Yes 📝 N  | 10             |

Song 2



| Section 5. Relationships not severed above   |
|--|
| Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Song has nothing to disclose.  |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Song 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Luo 1



| Section 1.  | Identifying Inform                                     | nation   |   |  |
|---|--|--|---|--|
| 1. Given Name (Fi<br>Suxia                                | rst Name)  | 2. Surname (Last Name)<br>Luo                              | -   | . Date<br>4-April-2020   |
| 4. Are you the cor  | responding author?                                     | Yes ✓ No   | Corresponding Author's Name<br>Baijun Fang                          | 2  |
| 5. Manuscript Title<br>Preliminary stud<br>myeloma (MM) o | y on the relationship ar                               | mong stem cell markers, d                                  | rug resistance and PI3K signa                                       | ling pathway in multiple   |
| 6. Manuscript Ide<br>TCR-19-2116                          | ntifying Number (if you kr                             | now it)  |   |  |
|   |  |  |   |  |
| Section 2.  | The Work Under Co                                      | onsideration for Public                                    | cation  |  |
| any aspect of the s<br>statistical analysis,              | ubmitted work (including                               | but not limited to grants, da                              | a third party (government, comr<br>ta monitoring board, study desig | mercial, private foundation, etc.) for<br>gn, manuscript preparation,                                  |
|   | l .  |  |   |  |
| Section 3.  | Relevant financial                                     | activities outside the s                                   | submitted work.   |  |
| of compensation clicking the "Add                         | n) with entities as descri<br>I +" box. You should rep | bed in the instructions. Us<br>port relationships that wer |   | ionships (regardless of amount<br>d as many lines as you need by<br><b>nths prior to publication</b> . |
| Are there any rel   | evant conflicts of intere                              | est? Yes ✓ No  |   |  |
|   | I  |  |   |  |
| Section 4.  | Intellectual Proper                                    | ty Patents & Copyric                                       | Jhts  |  |
| Do you have any   | patents, whether plan                                  | ned, pending or issued, br                                 | oadly relevant to the work?   | ☐ Yes 🗸 No   |

Luo 2



| Section 5.                |   |
|---------------------------|---|
| Section 5.                | Relationships not covered above   |
|                           | lationships or activities that readers could perceive to have influenced, or that give the appearance of acing, what you wrote in the submitted work?   |
| Yes, the follow           | ring relationships/conditions/circumstances are present (explain below):  |
| ✓ No other relati         | ionships/conditions/circumstances that present a potential conflict of interest   |
|                           | nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>nals may ask authors to disclose further information about reported relationships. |
| Section 6.                | Disclosure Statement  |
| Based on the above below. | ve disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |
| Dr. Luo has nothir        | ng to disclose.   |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Luo 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Fang 1



| Section 1.  | Identifying Inform         | ation         |                                    |                |   |
|---|----------------------------|---------------|------------------------------------|----------------|---|
| 1. Given Name (Fi<br>Baijun                               |                            |               | e (Last Name)                      |                | 3. Date<br>14-April-2020  |
| 4. Are you the cor  | responding author?         | <b>√</b> Yes  | No                                 |                |   |
| 5. Manuscript Title<br>Preliminary stud<br>myeloma (MM) o | y on the relationship ar   | mong stem     | cell markers, drug resistance ar   | nd PI3K signa  | aling pathway in multiple   |
| 6. Manuscript Idei<br>TCR-19-2116                         | ntifying Number (if you kr | ow it)        |                                    |                |   |
|   |                            |               |                                    |                |   |
| Section 2.  | The Work Under Co          | onsiderati    | on for Publication                 |                |   |
| any aspect of the s<br>statistical analysis,              | ubmitted work (including   | but not limit | red to grants, data monitoring boa |                | nmercial, private foundation, etc.) for ign, manuscript preparation,                              |
| Section 3.  |                            |               |                                    |                |   |
| Jeetholi J.   | Relevant financial         | activities (  | outside the submitted wor          | rk.            |   |
| of compensation   | n) with entities as descri | bed in the i  |                                    | ach entity; ac | tionships (regardless of amount<br>dd as many lines as you need by<br>onths prior to publication. |
| Are there any rel   | evant conflicts of intere  | est? Ye       | es 🗸 No                            |                |   |
|   | ı                          |               |                                    |                |   |
| Section 4.  | Intellectual Proper        | ty Pater      | ts & Copyrights                    |                |   |
| Do you have any   | patents, whether plan      | ned, pendin   | g or issued, broadly relevant to   | o the work?    | ☐ Yes ✓ No  |

Fang 2



| Section 5                 |   |
|---------------------------|---|
| Section 5.                | Relationships not covered above   |
|                           | ationships or activities that readers could perceive to have influenced, or that give the appearance of icing, what you wrote in the submitted work?  |
| Yes, the follow           | ing relationships/conditions/circumstances are present (explain below):   |
| ✓ No other relati         | onships/conditions/circumstances that present a potential conflict of interest  |
|                           | nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>hals may ask authors to disclose further information about reported relationships. |
| Section 6.                | Disclosure Statement  |
| Based on the above below. | re disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |
| Dr. Fang has noth         | ing to disclose.  |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Fang 3